Results 71 to 80 of about 2,166,017 (392)

Bypassing the build-up phase for oral immunotherapy in shrimp-allergic children

World Allergy Organization Journal
Background: Oral immunotherapy is an effective treatment for food allergies; however, its use in clinical practice is limited by resources and lack of standardized protocols for foods other than peanut.
Ann-Marie M. Schoos, MD, PhD, DMSc, Edmond S. Chan, MD, Tiffany Wong, MD, Stephanie C. Erdle, MD, Alanna Chomyn, MD, Lianne Soller, PhD, Raymond Mak, MD   +6 more
doaj   +1 more source

Mimotope mapping as a complementary strategy to define allergen IgE-epitopes: peach Pru p 3 allergen as a model. [PDF]

, 2008
Lipid transfer proteins (LTPs) are the major allergens of Rosaceae fruits in the Mediterranean area. Pru p 3, the LTP and major allergen of peach, is a suitable model for studying food allergy and amino acid sequences related with its IgE-binding ...
Compes, Esther, Cuesta-Herranz, Javier, Díaz Perales, Araceli, Pacios, Luis F., Palacín Gómez, Aranzazu, Salcedo Duran, Gabriel, Sánchez-Monge Laguna de Rins, Rosa, Tordesillas Villuendas, Leticia   +7 more
core   +2 more sources

Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio‐Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Neuroblastoma (NB) with central nervous system (CNS) metastases is rare at diagnosis, but occurs more often during relapse/progression. Patients with CNS metastases face a dismal prognosis, with no standardized curative treatment available.
Vicente Santa‐Maria Lopez, Anna Felip‐Badia, Marina Caballero‐Bellon, Nazaret Sanchez‐Sierra, Alicia Castañeda, Moira Garraus, Maite Gorostegui, Margarida Simão‐Rafael, Juan Pablo Muñoz, Marta Perez‐Somarriba, Salvador Mañe, Mariana Cecilia Planells, Sara Perez‐Jaume, Jaume Mora   +13 more
wiley   +1 more source

Peanut allergy: Beyond the oral immunotherapy plateau

Clinical and Translational Allergy, 2021
Background There are a lack of disease‐modifying treatments for peanut allergy, which is lifelong in most instances. Oral immunotherapy has remained at the forefront of prospective treatments, though its efficacy is consistently undermined by the risk of
Kelly Bruton, Paul Spill, Derek K. Chu, Susan Waserman, Manel Jordana   +4 more
doaj   +1 more source

Peanut allergy and oral immunotherapy [PDF]

Hong Kong Medical Journal, 2019
Peanut allergy is the commonest cause of food-induced anaphylaxis in the world, and it can be fatal. There have been many recent improvements to achieve safe methods of peanut desensitisation, one of which is to use a combination of anti-immunoglobulin E and oral immunotherapy.
T H, Lee, J K C, Chan, P C, Lau, W P, Luk, L H, Fung   +4 more
openaire   +2 more sources

Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy

Allergy. European Journal of Allergy and Clinical Immunology, 2021
The benefit of daily administration of Peanut (Arachis hypogaea) Allergen Powder‐dnfp (PTAH)—formerly AR101—has been established in clinical trials, but limited data past the first year of treatment are available.
M. Fernández-Rivas, A. Vereda, B. Vickery, Vibha Sharma, C. Nilsson, A. Muraro, J. Hourihane, A. DunnGalvin, G. du Toit, K. Blumchen, K. Beyer, Alexander D. Smith, R. Ryan, D. Adelman, S. Jones   +14 more
semanticscholar   +1 more source

Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background B‐cell lymphoblastic lymphoma (B‐LBL) represents a rare variety of non‐Hodgkin lymphoma, with limited research on its biology, progression, and management. Methods A retrospective analysis was performed on the clinical characteristics of 256 patients aged ≤18 years who received treatment under the China Net Childhood Lymphoma (CNCL)‐
Zhijuan Liu, Jian Wang, Ling Jin, Yanlong Duan, Fu Li, Yueping Jia, Leping Zhang, Xiaojun Yuan, Wei Liu, Ying Liu, Ansheng Liu, Mincui Zheng, Yunpeng Dai, Lian Jiang, Lirong Sun, Xiaowen Zhai, Rong Liu, Chunju Zhou, Zifen Gao, Yonghong Zhang, Xiaomei Yang   +20 more
wiley   +1 more source

DENDRITIC CELL DIFFERENTIATION BLOCKED BY PRIMARY EFFUSION LYMPHOMA-RELEASED FACTORS IS PARTIALLY RESTORED BY INHIBITION OF P38 MAPK [PDF]

, 2010
To better understand the molecular mechanisms underlying the dendritic cell (DC) defects in cancer, we analyzed which signaling pathway is implicated in the abnormal monocyte differentiation into DC determined by the presence of Primary effusion lymphoma
CIRONE, Mara, DI RENZO, Livia Maria, FAGGIONI, Alberto, FRATI, Luigi, G. Borgia, G. Lucania, TRIVEDI, PANKAJ   +6 more
core   +2 more sources

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Effect of Hypertension on Outcomes of High-Risk Patients After BCG-Treated Bladder Cancer [PDF]

, 2015
Immunotherapy with Bacillus Calmette Guerin (BCG) is the most efficacious treatment for high-risk bladder cancer (BC) (Ta/T1 or carcinoma in situ) to reduce the risk of recurrence.
Alberto, Bovo, Alessandro, Crestani, DAL MORO, Fabrizio, Marina P., Gardiman, Roberto, Vettor, Zattoni, Filiberto   +5 more
core   +1 more source